This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Fatty acid binding protein 5 psoriasis-associated (FABP5; EFABP)	*In vitro* and mouse studies suggest FABP5 inhibition could help treat breast cancer. In mouse embryonic fibroblasts, vector-mediated overexpression of FABP5 caused oncogenic transformation and increased cell proliferation, migration and invasion compared with normal FABP5 expression. In a transgenic mouse model for epidermal growth factor receptor (EGFR)-driven breast cancer, *Fabp5* knockout suppressed mammary tumor development and decreased EGFR signaling compared with no knockout. Ongoing studies include creating FABP5 inhibitors in sufficient quantities for preclinical testing. *SciBX* 6(26); doi:10.1038/scibx.2013.648 Published online July 11, 2013	Patent application filed covering FABP5 inhibitors and their use in cancer; available for licensing	Levi, L. *et al. Cancer Res.*; published online May 30, 2013; doi:10.1158/0008-5472.CAN-13-0384 **Contact:** Noa Noy, Case Western Reserve University School of Medicine, Cleveland, Ohio e-mail: nxn51@case.edu